Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
35
NCT02027805
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 5, 2014
Completion: Nov 3, 2016
NCT04128319
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
Phase: Phase 3
Start: Nov 21, 2019
Completion: Feb 17, 2020
NCT04934670
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
Start: Jun 16, 2022
Completion: Jan 19, 2023